Q-State Biosciences has developed a set of optimized antisense oligonucleotides (ASOs) that may serve as potential therapies for Parkinson’s disease patients with specific mutations, the company announced. These ASO candidates are designed for patients carrying mutations in the GBA gene, a key genetic risk factor for the disease’s development. Their development is the first milestone reached under an agreement between Q-State and Chamishi Therapeutics, a company it launched together with the Silverstein Foundation for Parkinson’s with GBA. Chamishi focuses…

You must be logged in to read/download the full post.